Because the sulfathiazole content of the brain and cerebrospinal fluid is admittedly low compared to that of the blood during medication, it has recently been (Table  I ). All fatalities were autopsied and those showing insufficient pneumococcic infection to explain death were not included in the experiment.
Because the sulfathiazole content of the brain and cerebrospinal fluid is admittedly low compared to that of the blood during medication, it has recently been claimed, in the absence of pertinent experimental or clinical data, that sulfathiazole is of little or no value in treating bacterial meningitis (1 to 4). Although it is not the purpose of this paper to advise the continued use of sulfathiazole in clinical cases of meningitis or to recommend to the clinician the use of any one of the sulfonamides in preference to the others, the experimental data presented and the clinical cases collected from the literature show that the above claim (1 to 4), as well as certain other disseminated opinions, require modification.
METHOD
Two hundred rats of approximately 200 grams weight were lightly anesthetized with ether and infected intracranially with approximately one fatal dose of Type II pneumococci. The animals were divided into five groups: one served as control; the remaining four groups were treated orally with 100 mgm. of the various drugs suspended in 0.5 cc. of 15 per cent gum acacia 6, 22, 46, and 96 hours after infection. One group was treated with sulfanilamide, one with sulfapyridine, one with sulfathiazole, and the last with sulfamethylthiazole (Table  I ). All fatalities were autopsied and those showing insufficient pneumococcic infection to explain death were not included in the experiment.
To ascertain the relationship between the concentration of sulfathiazole in the blood and brain, 45 -similarly infected rats were given 100 mgm. of drug orally, followed by 100 mgm. 8 hours and 24 hours later. At the intervals indicated in Figure 1 a number of rats were lightly etherized and 0.5 cc. of blood was withdrawn by cardiac puncture for analysis. No rat was bled more frequently than once during 24 hours. Rats were sacrificed after the 25-, 26-, 27-, 28-, 29-, and 30-hour bleedings and the drug content of the brain was determined. The analytical method employed was a modification of that of Bratton and Marshall (5) and has been shown statistically to give significantly higher recovery of sulfathiazole from blood, especially at 1: 20 dilution (6). Table I The concentration of sulfathiazole in the blood of rats receiving comparable treatment lay along a fairly smooth curve during the 7 hours following the first treatment (Figure 1 ). During the 6 hours following the 24-hour treatment, the con-
RESULTS

Reference to
BLE I
Type II pneumococcic meningitis in rats Number of deaths daily during 21 The brains of rats killed during the interval when and vascular scars in the cerebral cortex with blood concentrations varied from 3.5 to 10 mgm. clusters of phagocytic cells, hemosiderin deposits per cent, and averaged 5 to 6 mgm. per cent, and foci of calcification. showed drug concentrations which varied from The infecting dose was purposely kept low so traces to 3 mgm. per cent and averaged approxi-that successful treatment with the various drugs mately 1.6 mgm. per cent.
remained below the level known to cause kidney damage and its sequelae in rats (9 to 11).
DISCUSSION
Because the greatest difference in group survival In a previous report (7) it was demonstrated was 9 per cent, the results were tested for sigthat pneumococcic meningitis in rats is at least as nificance by the x2 method. Taking the probasevere as in man. In untreated animals, the oc-bility value of 0.05 as the criterion of significance, currence of empyema of the cerebral ventricles it was found that the differences observed among and of the central canal of the cord was not un-the treated groups were without statistical sigcommon. Extensions of the purulent meningitis nificances into the nervous parenchyma occurred and were This proof that sulfanilamide, sulfapyridine, often associated with abscesses. Proof that the and sulfathiazole are equally effective in experiinfection was not eliminated before lesions had mental pneumococcic meningitis of rats infected become established was seen in the disturbances in with the Binda Type II strain raises the interestgait and equilibrium in treated animals which ing question of the relative importance of a high recovered. Anatomic proof was obtained in the concentration of free drug in the cerebrospinal histologic sections of the brain and cord of these fluid for successful chemotherapy of meningitis. animals (8) . The significant findings included The blood of infected rats. which received 300 mgm. of sulfathiazole in 24 hours (Figure 1 ), averaged 5 to 6 mgm. per cent of free drug, while the brains averaged 1.6 mgm. per cent and occasionally contained considerably less than 1 mgm. per cent.
Chemotherapeutic results of clinical meningitis as collected from the literature The successful treatment with sulfathiazole of experimental pneumococcic meningtis in rats has its counterpart in the treatment of clinical meningitis. Table II lists not only 4 typed cases of pneumococcic meningitis but one case of streptococcic meningitis, 9 cases of staphylococcic meningitis, and 125 cases of meningococcic meningitis, the cure of which was attributed to therapy with sulfathiazole or its sodium salt.
The evaluation of the clinical efficacy of the various sulfanilamide drugs has resulted in rules which, on the whole, seem to be workable. However, several opinions disseminated in the medical literature appear, on the basis of subsequent clinical experience, to require modification. A case in point was the early and persistent assertions, frequently based on none too critical animal experiments, that sulfanilamide was of little or no value in pneumococcic infections (12 to 17) or was of value in treating only Type III pneumococcic infections (18 to 20). Disregard of these asser- tions, fostered perhaps by the successful treatment of experimental Type I, II, and III pneumococcic meningitis in rats (7, 21, 22) , has resulted in reports of 55 cases of pneumococcic meningitis whose recovery is attributed to sulfanilamide and, in several instances, to the less effective neoprontosil (Table III) . Among the recoveries, 42 cases were typed and 16 received serum in conjunction with the chemotherapy. Similarly, sulfapyridine, which was considered the drug of choice for treating pneumococcic infections before the advent of sulfathiazole, is reported to have saved 88 cases of pneumococcic meningitis (Table IV) . In this series, 57 cases were typed and 29 received type-specific serum as an adjuvant to the chemotherapy. A number of recoveries which received both sulfanilamide and sulfapyridine were not included in Tables III and IV. t NaSP Sodium salt of sulfapyridine.
In view of the fact that a review of the literature prior to the introduction of the sulfonamides showed but 30 recoveries from pneumococcic meningitis during the preceding 15 years (23), the report of 55 cures by sulfanilamide within the last 4 years, and four cures by sulfathiazole within less than one year leaves no reasonable doubt of the efficacy of these drugs. However, the conclusion reached in a recent review (24) that sulfanilamide and sulfapyridine were equally effective in treating pneumococcic meningitis is almost as unjustified on the basis of the statistical evidence available as the assertion that sulfanilamide and sulfathiazole are of questionable value in this disease.
Because of the lack of decisive data at present, it is not possible to judge which of the sulfonamide drugs, if any, is significantly superior in the clinical treatment of pneumococcic meningitis. Future decision on this point awaits not only the accumulation of sufficiently large numbers of cases treated with the various sulfonamides but the inclusion of the fatalities along with the cures in the data reported. Pertinent information concerning the efficacy of new drugs may also be obtained by the direct study of experimental pneumococcic meningitis and it is suggested that this method be used in preference to a reliance on the drug concentration in the cerebrospinal fluid. CONCLUSIONS 1. Sulfanilamide, sulfapyridine, sulfathiazole, and sulfamethylthiazole are equally effective in the treatment of experimental Type II (Binda) pneumococcic meningitis in rats.
2. The sulfathiazole content of the brains of rats which received 300 mgm. of sulfathiazole orally in 24 hours averaged 1.6 mgm. per 100 grams at the time the blood averaged 5 to 6 mgm. per 100 cc.
3. Data are presented which show that clinical pneumococcic meningitis has been successfully treated with sulfanilamide as well as with sulfapyridine. 4 . Other clinical data show pneumococcic, streptococcic, staphylococcic and meningococcic meningitis recoveries which were attributed to sulfathiazole therapy in spite of the generally recognized low concentration of this drug in the cerebrospinal fluid.
5. Because of the lack of decisive data at present, it is not possible to judge which of the sulfonamide drugs is significantly superior in the clinical treatment of pneumococcic meningitis. Future decision on this point awaits not only the accumulation of sufficiently large numbers of cases treated with the various sulfonamides but also the inclusion of the fatalities along with the cures in the data reported.
Note: While this paper was in press, Davis (25) presented experimental evidence which indicated that the sulfonamides are more or less closely bound to the albumen fraction of the blood, and for this reason the ratio of their "apparent" concentration in the blood to their actual concentration in the cerebrospinal fluid should not be used as a guide to the choice of drug for treating meningitis.
